Home Festival constitute AIVITA Biomedical CEO Dr Hans Keirstead to chair panel and address at...

AIVITA Biomedical CEO Dr Hans Keirstead to chair panel and address at World Immunotherapy Congress in Europe

3
0

IRVINE, Calif., November 8, 2021 / PRNewswire / – AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, today announced that President and CEO Dr. Hans S. Keirstead will chair a panel and speak on consecutive days at the World Immunotherapy Congress Europe. The congress is part of the Festival of organic products which takes place in Basel, Switzerland, November 9-11. The details of Dr Keirstead’s address are as follows:

Main round table: What future for immunotherapy for oncology and infectious diseases?
When: Tuesday, November 9, 10:00 am CEST
Panelists: Christian klein, Head of Oncology Programs, Head of Cancer Immunotherapy Department, Roche Innovation Center Zurich; Jessica flechtner, Scientific Director, Genocea Biosciences, Hans keirstead, Chairman and CEO of AIVITA Biomedical.
Site: Basel Congress Center – Basel, Switzerland

Presentation: Advanced clinical development of personalized vaccine platform technology for cancer and COVID-19
When: Wednesday November 10, 11:50 a.m. CEST
Site: Basel Congress Center – Basel, Switzerland

About AIVITA Biomedical

Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. uses its expertise in stem cell growth and high purity directed differentiation to enable safe, efficient and economical manufacturing systems that support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, the tumor initiator cells, with a unique pan-antigenic approach that targets all of the patient’s cancer-specific neoantigens. Our patient-specific cancer treatments have shown tremendous promise in eradicating tumors without harmful side effects in clinical studies of melanoma and glioblastoma. Our COVID-19 vaccine activation kit is intended for emerging countries allowing the production of point-of-care vaccines in poorly equipped facilities by poorly trained third-party technicians.

Caution Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, if applicable. Forward-looking statements include, without limitation, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. In addition, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data relating to our business and our industry, including projections based on a number of assumptions that we consider reasonable and the most significant compared to projections at the date of this communication. If any of our assumptions turn out to be incorrect, our actual results may differ materially from our projections based on those assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy the securities described herein.

SOURCE AIVITA Biomedical, Inc.


Source link